By Dean Seal
Eli Lilly has unleashed another wave of litigation against four telehealth brands in its widening legal war with sellers of alternative versions of its popular diabetes and weight-loss drugs.
The large drugmaker on Wednesday filed four lawsuits targeting Mochi Health, Fella & Delilah Health, Willow Health and Henry Meds over their sales of knockoff versions of tirzepatide, the active ingredient in its diabetes drug Mounjaro and obesity drug Zepbound.
Each of the telehealth companies are alleged by Lilly to have misled consumers and patients in their marketing of the compounded tirzepatide products and driven them away from safer medicines.
Representatives for the four companies didn't immediately respond to requests for comment.
The actions filed in California federal courts are Lilly's latest attempt to crack down on the sale of custom-made versions of its drugs, which have faced shortages due to high demand, leading to a surge of cheaper, alternative versions.
Lilly has filed lawsuits against med-spas, wellness centers and other entities for selling products that purportedly containing tirzepatide, claiming in some cases that the defendants falsely label their products as Mounjaro and Zepbound, as being the same as those drugs, as being part of Eli Lilly's clinical trials, or as being approved by federal regulators.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
April 23, 2025 10:54 ET (14:54 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。